Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
Public ClinicalTrials.gov record NCT00365820. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Tegaserod and Placebo Given Orally for 12 Weeks for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy and safety of tegaserod in opioid-induced constipation in patients with non-cancer pain.
Study identification
- NCT ID
- NCT00365820
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 670 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2006
- Primary completion
- Mar 31, 2007
- Completion
- Mar 31, 2007
- Last update posted
- Apr 19, 2012
2006 – 2007
United States locations
- U.S. sites
- 59
- U.S. states
- 26
- U.S. cities
- 55
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Mobile | Alabama | 36608 | — |
| Investigative Site | Phoenix | Arizona | 85029 | — |
| Investigative Site | Phoenix | Arizona | 85050 | — |
| Investigative Site | Tucson | Arizona | 85712 | — |
| Investigative Site | North Little Rock | Arkansas | 72117 | — |
| Investigative Site | Buena Park | California | 90620 | — |
| Investigative Site | Downey | California | 90240 | — |
| Investigative Site | Encinitas | California | 92024 | — |
| Investigative Site | Fountain Valley | California | 92708 | — |
| Investigative Site | La Jolla | California | 92037 | — |
| Investigative Site | Los Angeles | California | 90073 | — |
| Investigative Site | Mission Viejo | California | 92691 | — |
| Investigative Site | San Diego | California | 92103 | — |
| Investigative Site | San Francisco | California | 94115 | — |
| Investigative Site | Torrance | California | 90505 | — |
| Investigative Site | Northglenn | Colorado | 80234 | — |
| Investigative Site | Bristol | Connecticut | 06010 | — |
| Investigative Site | DeLand | Florida | 32720 | — |
| Investigative Site | Jacksonville | Florida | 32207 | — |
| Investigative Site | Largo | Florida | 33773 | — |
| Investigative Site | Miami | Florida | 33176 | — |
| Investigative Site | New Smyrna Beach | Florida | 32168 | — |
| Investigative Site | Springhill | Florida | 34609 | — |
| Investigative Site | Tampa | Florida | 33607 | — |
| Investigative Site | Belleville | Illinois | 62220 | — |
| Investigative Site | Chicago | Illinois | 60640 | — |
| Investigative Site | Avon | Indiana | 46123 | — |
| Investigative Site | Evansville | Indiana | 47714 | — |
| Investigative Site | Indianapolis | Indiana | 46254 | — |
| Investigative Site | Overland Park | Kansas | 66212 | — |
| Investigative Site | Prairie Village | Kansas | 66206 | — |
| Investigative Site | Shreveport | Louisiana | 71103 | — |
| Investigative Site | Boston | Massachusetts | 02118 | — |
| Investigative Site | Boston | Massachusetts | 02215 | — |
| Investigative Site | Omaha | Nebraska | 68114 | — |
| Investigative Site | Omaha | Nebraska | 68134 | — |
| Investigative Site | Pahrump | Nevada | 89048 | — |
| Novartis Pharmaceutical Corporation | East Hanover | New Jersey | 07936-1080 | — |
| Investigative Site | New York | New York | 10016 | — |
| Investigative Site | New York | New York | 10022 | — |
| Investigative Site | North Massapequa | New York | 11758 | — |
| Investigative Site | Charlotte | North Carolina | 28210 | — |
| Investigative Site | Greensboro | North Carolina | 27401 | — |
| Investigative Site | Monroe | North Carolina | 28112 | — |
| Investigative Site | Winston-Salem | North Carolina | 27103 | — |
| Investigative Site | Dayton | Ohio | 45440 | — |
| Investigative Site | Oklahoma City | Oklahoma | 73112 | — |
| Investigative Site | Portland | Oregon | 97232 | — |
| Investigative Site | Hershey | Pennsylvania | 17033-085 | — |
| Investigative Site | Levittown | Pennsylvania | 19056 | — |
| Investigative Site | Chattanooga | Tennessee | 37404 | — |
| Investigative Site | Beaumont | Texas | 77701 | — |
| Investigative Site | Colleyville | Texas | 76034 | — |
| Investigative Site | Corsicana | Texas | 75110 | — |
| Investigative Site | Houston | Texas | 77005 | — |
| Investigative Site | San Antonio | Texas | 78229 | — |
| Investigative Site | Salt Lake City | Utah | 84132 | — |
| Investigative Site | Charlottesville | Virginia | 22903 | — |
| Investigative Site | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00365820, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2012 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00365820 live on ClinicalTrials.gov.